Pharmaceutical and medicine manufacturing total R&D performance vs Autoimmune cell therapy and T-cell engager trial starts in United States

In 2023, pharmaceutical and medicine manufacturing total R&D performance in United States was 125,986 million USD; autoimmune cell therapy and T-cell engager trial starts was 5.

Change the pair

Compare different indicators

The series

Over time

United States, annual figures, spaced by time from 2022 to 2023 . Different units, drawn on separate scales and clipped to the years both series publish; earlier history stays on each indicator’s own page. Read the values, not the heights.

Pharmaceutical and medicine manufacturing total R&D performance

Unit: million USD · 2 observations

Line chart
Pharmaceutical and medicine manufacturing total R&D performancePharmaceutical and medicine manufacturing total R&D performance. 2 observations from 2022 to 2023, ranging from 116,073 million USD to 125,986 million USD. Latest value 125,986 million USD (2023). million USD 0 30,000 60,000 90,000 120,000 150,000 2022 2023 116,073 125,986
Pharmaceutical and medicine manufacturing total R&D performancePharmaceutical and medicine manufacturing total R&D performance. 2 observations from 2022 to 2023, ranging from 116,073 million USD to 125,986 million USD. Latest value 125,986 million USD (2023). million USD 0 50,000 100,000 150,000 2022 2023 116,073 125,986
Pharmaceutical and medicine manufacturing total R&D performancePharmaceutical and medicine manufacturing total R&D performance. 2 observations from 2022 to 2023, ranging from 116,073 million USD to 125,986 million USD. Latest value 125,986 million USD (2023). million USD 0 50,000 100,000 150,000 2022 2023 116,073 125,986
View the underlying data
Pharmaceutical and medicine manufacturing total R&D performance
Period Type Value
2022 Actual 116,073 million USD
2023 Actual 125,986 million USD
Source: NCSES · CC BY 4.0 · Full series

Autoimmune cell therapy and T-cell engager trial starts

Unit: count · 2 observations

Line chart
Autoimmune cell therapy and T-cell engager trial startsAutoimmune cell therapy and T-cell engager trial starts. 2 observations from 2022 to 2023, ranging from 2 to 5. Latest value 5 (2023). 0 1 2 3 4 5 2022 2023 2 5
Autoimmune cell therapy and T-cell engager trial startsAutoimmune cell therapy and T-cell engager trial starts. 2 observations from 2022 to 2023, ranging from 2 to 5. Latest value 5 (2023). 0 2 4 6 2022 2023 2 5
Autoimmune cell therapy and T-cell engager trial startsAutoimmune cell therapy and T-cell engager trial starts. 2 observations from 2022 to 2023, ranging from 2 to 5. Latest value 5 (2023). 0 2 4 6 2022 2023 2 5
View the underlying data
Autoimmune cell therapy and T-cell engager trial starts
Period Type Value
2022 Actual 2
2023 Actual 5
Source: ClinicalTrials.gov · CC BY 4.0 · Full series

Shared periods

Side by side

2 periods are published for both series in United States as annual figures on the same basis. Comparing anything else would mean comparing different periods.

Period Pharmaceutical and medicine manufacturing total R&D performance Autoimmune cell therapy and T-cell engager trial starts
2022 116,073 million USD NCSES 2 ClinicalTrials.gov
2023 125,986 million USD NCSES 5 ClinicalTrials.gov

Provenance

Where these numbers come from

Pharmaceutical and medicine manufacturing total R&D performance

Total cost of research and development performed by pharmaceutical and medicine manufacturing companies across all funding sources.

2 observations charted in United States · source organisations: NCSES

Autoimmune cell therapy and T-cell engager trial starts

Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.

2 observations charted in United States (of 6 annual records) · source organisations: ClinicalTrials.gov

Data published under CC BY 4.0. Series A as JSON · Series B as JSON

Keep exploring

Related